ReviewCancers2021
New Insights into Endometrial Cancer.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Prognostic value of pretreatment systemic immune-inflammation index in patients with endometrial cancer: a meta-analysis.Biomarkers in medicine · 2024Pooled it
- Is there an association between hyperandrogenic states in women and endrometrial cancer? A narrative review.Hormones (Athens, Greece) · 2026Review
- Enhancement of circular RNA 0002577 in serum exosomes in patients with endometrial cancer accelerates disease progression via general transcription factor II-I repeat domain-containing 1 (GTF2IRD1).Journal of gynecologic oncology · 2026Article
- Programmed cell death-1: from a T-cell immune checkpoint to a regulator of Natural Killer cell biology.Frontiers in cell and developmental biology · 2026Review
- The RNA-binding protein ELAVL1 promotes Beclin1-mediated cellular autophagy and thus endometrial cancer development by affecting LncRNA-neat stability.Cancer biology & therapy · 2025Article
- Mathematical model of optimal control for endometrial cancer with treatments dostarlimab and chemotherapy using Caputo derivative.Scientific reports · 2025Article
- Clinical Utility of Pan-Immune Inflammation Value (PIV) in Predicting Prognosis of Endometrial Cancer.Journal of clinical medicine · 2025Article
- Global, regional, and national burden of uterine cancer among women aged 50 years and older from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.Journal of health, population, and nutrition · 2025Article
- Article
- Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes.Journal of clinical medicine · 2025Review
- From Genes to Clinical Practice: Exploring the Genomic Underpinnings of Endometrial Cancer.Cancers · 2025Review
- Development of a machine learning model for predicting the expression of proteins associated with targeted therapy in endometrial cancer.Frontiers in oncology · 2025Article
- Epidemiology, Real-World Treatment Patterns, and Patient Outcomes of Primary Advanced or Recurrent Endometrial Cancer in Germany between 2015 and 2021.Oncology research and treatment · 2025Article
- Assessment of the localization of chondroitin sulfate in various types of endometrial carcinoma.PloS one · 2024Article
- The identification of a PTEN-associated gene signature for the prediction of prognosis and planning of therapeutic strategy in endometrial cancer.Translational cancer research · 2023Article
- Time trend of global uterine cancer burden: an age-period-cohort analysis from 1990 to 2019 and predictions in a 25-year period.BMC women's health · 2023Article
- Circulating miRNAs as a Tool for Early Diagnosis of Endometrial Cancer-Implications for the Fertility-Sparing Process: Clinical, Biological, and Legal Aspects.International journal of molecular sciences · 2023Review
- Uterine Malignancy: Pathological Pattern and Changing Incidence in a Teaching Hospital in Jeddah, Saudi Arabia.Cureus · 2023Article
- CEP55 predicts the poor prognosis and promotes tumorigenesis in endometrial cancer by regulating the Foxo1 signaling.Molecular and cellular biochemistry · 2023Article
- New Strategies for Endometrial Cancer Detection and Management.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
EC is the most common cancer in the female genital tract in developed countries, and with its increasing incidence due to risk factors, such as aging and obesity, tends to become a public health issue. Although EC is a hormone-dependent neoplasm, there are no recommendations for the determination of steroid hormone receptors in the tumor tissue and no hormone therapy has ever been assessed in the adjuvant setting. Furthermore, its immune environment has been slightly characterized, but recent evidences point out how EC microenvironment may increase self-tolerance by reducing the recruitment of cytotoxic immune cells to the tumor site and/or modifying their phenotype, making these cells no longer able to suppress tumor growth. Here we highlight insights for EC management from diagnosis to a desirable trend of personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.